Page 4,997«..1020..4,9964,9974,9984,999..5,0105,020..»

Research and Markets: Opportunities in Human Embryonic Stem Cell Products

Posted: Published on August 7th, 2013

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/5flxzm/opportunities_in) has announced the addition of the "Opportunities in Human Embryonic Stem Cell Products" report to their offering. Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reached four to five days post-fertilization. Human embryonic stem cells are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body. Human embryonic stem cells were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow hESCs derived from human blastocysts. Federal funds to support hESC research became available on August 9, 2001, when President Bush announced his decision regarding federal funding for hESC research. Because of their plasticity and unlimited capacity for self-renewal, hESCs have been proposed for use in wide range of applications, including toxicology testing, tissue engineering, cellular … Continue reading →

Posted in Stem Cell Research | Comments Off on Research and Markets: Opportunities in Human Embryonic Stem Cell Products

Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on International Stem Cell Corporation

Posted: Published on August 7th, 2013

NEW YORK, NY--(Marketwired - Aug 6, 2013) - Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview (EIO) on International Stem Cell Corporation (OTCQB: ISCO). The full 72-page report is available on Crystal Research Associates' website at http://www.crystalra.com. International Stem Cell Corporation ("ISCO" or "the Company") is a biotechnology company focused on therapeutic applications of human parthenogenetic stem cells (hpSCs) to treat diseases of the brain, liver, and eye, as well as on the development and commercialization of biomedical products. According to the Company, hpSC is the only histocompatible stem cell platform capable of generating stem cell lines that can immune-match millions of people. ISCO has focused its therapeutic efforts in three markets where cell therapy has been clinically proven, but where there is a shortage of safe cells or tissue: (1) Parkinson's disease (PD); (2) inherited metabolic liver disease; and (3) corneal blindness. The Company believes these markets may have a combined revenue potential of over $5 billion. ISCO is also developing a stem cell bank, UniStemCell, which already contains enough histocompatible stem cell lines to immune-match over 75 million people. In addition, the Company produces and markets specialized cells and growth media for … Continue reading →

Posted in Stem Cell Research | Comments Off on Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on International Stem Cell Corporation

GPI "Stem Cell Action Award" Honorees Advancing Stem Cell Research, Funding and Advocacy

Posted: Published on August 7th, 2013

SAN DIEGO, Aug. 6, 2013 (GLOBE NEWSWIRE) -- This year's Stem Cell Action Award honorees, announced today, have funded millions of dollars in stem cell research; raised the standard in medical research journalism; and worked to educate patients, researchers and the entire stem cell community. The 2013 Stem Cell Action Award honorees: Since 2005, Genetics Policy Institute (GPI) has honored the stem cell community's top innovators, leaders, and champions at the Stem Cell Action Awards Dinner at the annual World Stem Cell Summit. The awards will be presented at the 9th Annual Stem Cell Action Awards dinner, Tuesday, December 5, during the 2013 World Stem Cell Summit (WSCS13) at the Manchester Grand Hyatt San Diego, in San Diego, California. "The work done by this year's honorees has directly advanced stem cell research through research, funding and advocacy. They are passionate about making change and we are proud to honor their achievements," said Bernard Siegel, Executive Director of GPI. "These five honorees are sharing knowledge, building infrastructure and supporting the research needed to find cures and alleviate human suffering." Previous Stem Cell Action awardees have included Maryland Governor Martin O'Malley, Research!America, Juvenile Diabetes Research Foundation (JDRF), Michael J. Fox, Robert Klein, … Continue reading →

Posted in Stem Cell Research | Comments Off on GPI "Stem Cell Action Award" Honorees Advancing Stem Cell Research, Funding and Advocacy

Could genetic testing help doctors treat pain more effectively?

Posted: Published on August 7th, 2013

Approximately $300 billion is wasted each year on drugs that do not work in people who carry certain genes, according to experts. These people never receive the full benefit from these drugs, while others experience dangerous side effects. In order to treat individuals who have had many failures with drugs, some doctors are turning towards personalized medicine - which provides a method by which doctors can customize medication regimens so that they are effective from the start. What role does genetics have in pain? Research shows that genetic factors account for a substantial proportion of all elements contributing to a patients response to drugs (others include age, sex, weight, general health and liver function). Genes provide your body with instructions for making enzymes, which help break down drugs in your system, allowing your body to benefit from the medicine. Differences in your enzymes can affect how your body metabolizes a drug and how long the drug stays your body - and thus, how well drugs may work in an individual. In particular, common pain medications require activation by an enzyme called CYP2D6 to become effective. Approximately half of patients have genes that alter the function of CYP2D6. Testing for these … Continue reading →

Comments Off on Could genetic testing help doctors treat pain more effectively?

BioTime’s Subsidiary OncoCyte Corporation Publishes Data on the Gene FSIP1 as a Breast Cancer-Specific Marker

Posted: Published on August 6th, 2013

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) and BioTimes subsidiary OncoCyte Corporation today announced the publication of a scientific report on the gene FSIP1 and its potential as a marker for breast cancer. The paper, published in the peer-reviewed journal Biomarkers in Medicine and available online today, describes the microarray-based approach used to identify FSIP1 as a breast cancer biomarker with significantly elevated expression in breast tumors expressing the estrogen receptor, which represents 70-80% of all breast cancers. In addition to elevated gene expression, FSIP1 protein was also expressed within tumors at significant levels whereas little to no expression was found in most normal tissues, including healthy breast tissue. Combined, these findings lay the foundation for novel diagnostic and therapeutic strategies, including the measurement of FSIP1 in the blood as a screen for the presence of cancer, as well as targeting of FSIP1 as an antigen in cancer immunotherapy approaches. Based on large unmet need, market size, and data generated thus far from patient sample screening, OncoCyte is initially focusing its efforts on identifying biomarkers that may be used to detect and monitor breast and bladder cancers. OncoCyte has been developing, characterizing, and manufacturing monoclonal antibodies for use in … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on BioTime’s Subsidiary OncoCyte Corporation Publishes Data on the Gene FSIP1 as a Breast Cancer-Specific Marker

StemCells, Inc. Announces Webcast to Discuss Second Quarter 2013 Financial Results and Business Update

Posted: Published on August 6th, 2013

NEWARK, Calif., Aug. 5, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the second quarter ended June 30, 2013 after the market close on Wednesday, August 7. In connection with this announcement, StemCells will host a conference call and webcast to discuss its results and an update on its business at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. Eliseo Salinas, MD, Executive Vice President and Head of Research & Development at StemCells, will be on the call to discuss the Company's recently announced two-year data in patients with Pelizaeus-Merzbacher disease (PMD). Interested parties are invited to listen to the call over the Internet by accessing the Investors section of the Company's website at http://www.stemcellsinc.com. Webcast participants should allot extra time before the webcast begins to register and, if necessary, download and install audio software. An archived version of the webcast will also be available for replay on the Company's website beginning approximately two hours following the conclusion of the live call and continuing for a period … Continue reading →

Comments Off on StemCells, Inc. Announces Webcast to Discuss Second Quarter 2013 Financial Results and Business Update

Osiris Therapeutics Announces Second Quarter 2013 Financial Results

Posted: Published on August 5th, 2013

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today its results for the second quarter of 2013. Highlights and Recent Developments We are very pleased with the return our new sales team is delivering on our investments in commercial infrastructure as demonstrated by our continued revenue growth, said C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris. We are also excited about the progress of Protocol 302, our randomized, controlled clinical trial evaluating Grafix for chronic diabetic foot ulcers. By balancing our commercial and developmental activities, we continue to advance towards our goal of creating a profitable business in cell therapy by providing best-in-class products and service. Second Quarter Financial Results Product revenues during the second quarter of 2013 were $5.3 million, compared to $1.6 million during the second quarter of 2012, an increase of 231%. Gross margin during the second quarter was 72% compared to 66% during the second quarter of 2012. Gross profit was $3.8 million during the second quarter of 2013 and $1.1 million during the same period of 2012. The net … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Osiris Therapeutics Announces Second Quarter 2013 Financial Results

Stem cells found in gum tissue can fight inflammatory disease

Posted: Published on August 5th, 2013

Aug. 5, 2013 Stem cells found in mouth tissue can not only become other types of cells but can also relieve inflammatory disease, according to a new Ostrow School of Dentistry of USC study in the Journal of Dental Research. The cells featured in the study are gingival mesenchymal stem cells (GMSC), which are found in the gingiva, or gum tissue, within the mouth. GMSC, like other stem cells, have the ability to develop into different types of cells as well as affect the immune system. "Gingiva is very unique in our body," says Professor Songtao Shi, the study's senior author. "It has much less inflammatory reaction and heals much faster when compared to skin." Previously, the developmental origins and abilities of GMSC hadn't been fully illustrated. This study shows that there are two types of GMSC: those that arise from the mesoderm layer of cells during embryonic development (M-GMSC) and those that come from cranial neural crest cells (N-GMSC). The cranial neural crest cells develop into many important structures of the head and face, and 90 percent of the gingival stem cells were found to be N-GMSC. The two types of stem cells vary dramatically in their abilities. N-GMSC … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Stem cells found in gum tissue can fight inflammatory disease

Pembroke mom fights for accelerated cure for son

Posted: Published on August 5th, 2013

PEMBROKE New England Patriots players surrounded her, yet Christine McSherry of Pembroke could not take her eyes off 10-year-old Max as he ran around like a normal kid at a Patriots training camp event last August. Max, like McSherry's own 17-year-old son, Jarrett, suffers from Duchenne muscular dystrophy a disorder, primarily seen in boys, that is caused by a mutation in the gene that codes for the muscle protein dystrophin. Other forms of muscular dystrophy cause a decrease in dystrophin, but boys with Duchenne do not produce any of the protein. Many of them are confined to a wheelchair by age 12. There is no approved treatment for Duchenne muscular dystrophy, which ultimately causes early death. But as McSherry watched the hopping and skipping of Max, a boy whose strength was quickly decreasing a year prior, she felt reason for hope. "There was a significant difference," McSherry said recently. "This kid, you would have no idea there was anything wrong with him." The hope comes in the form of eteplirsen, a clinical drug made by Cambridge-based Sarepta Therapeutics. It has shown great potential for stopping the advance of Duchenne. Founder of the Jett Foundation for fighting Duchenne muscular dystrophy, McSherry … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Pembroke mom fights for accelerated cure for son

NHL All-Star Ryan Getzlaf to Host 3rd Annual Getzlaf Golf Shootout to Benefit Cure Duchenne on September 8

Posted: Published on August 5th, 2013

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Ryan Getzlaf, captain of the Anaheim Ducks, is hosting the third annual Getzlaf Golf Shootout on September 8 to benefit CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy. Gold medalist and NHL All-Star Getzlaf, along with his Anaheim Ducks teammates including Corey Perry, Dustin Penner and Sauk Koivu, and other hockey players, celebrities and community leaders will participate in the golf tournament to support CureDuchenne. Scott Niedermayer, assistant coach of the Anaheim Ducks, Stanley Cup champion, Olympic gold medalist and Hockey Hall of Fame inductee, is also scheduled to participate. This charity event will be held at the Monarch Beach Golf Links in Dana Point on Sunday, September 8. Each foursome will be teamed up with a professional athlete or celebrity for a unique and exciting day on the green. A pre-golf dinner reception will be held at Sutra in Costa Mesa on Saturday, September 7 and will include a live and silent auction. Duchenne is a progressive muscle-wasting disease that impacts one in 3,500 boys. Boys are usually diagnosed at age 5, are in a wheelchair by 12 and most dont live past their mid-20s. CureDuchenne … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on NHL All-Star Ryan Getzlaf to Host 3rd Annual Getzlaf Golf Shootout to Benefit Cure Duchenne on September 8

Page 4,997«..1020..4,9964,9974,9984,999..5,0105,020..»